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ABSTRACT
Type 1 diabetes (T1D) is an autoimmune disease caused by the destruction of insulin-producing cells.
Due to the ability of apoptotic cells clearance to induce tolerance, we previously generated liposomes
rich in phophatidylserine (PS) –a feature of apoptotic cells– loaded with insulin peptides to mimic
apoptotic beta-cells. PS-liposomes arrested autoimmunity in experimental T1D through the induction
of tolerance. The aim of this study was to investigate the potential of several peptides from different
T1D autoantigens encapsulated in (PS)-liposomes for T1D prevention and to assess its safety. T1D auto-
antigens (Insulin, C-peptide, GAD65 and IA2) were encapsulated in PS-liposomes. Liposomes were
administered to the ’gold-standard’ model for the study of autoimmune T1D, the Non-Obese Diabetic
mouse, that spontaneously develop the disease. Safety and toxicity of liposomes were also determined.
Only PS-liposomes encapsulating insulin peptides decrease T1D incidence in the Non-Obese Diabetic
mouse model. Disease prevention correlates with a decrease in the severity of the autoimmune islet
destruction driven by leukocytes. PS-liposomes neither showed toxic effect nor secondary complica-
tions. Among the here referred autoantigens, insulin peptides are the best candidates to be encapsu-
lated in liposomes, like an artificial apoptotic cell, for the arrest of autoimmunity in T1D in a
safe manner.
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Introduction
An essential goal to both prevent and cure type 1 diabetes
(T1D) is to arrest the autoimmune reaction against b-cells.
Insulin is a key autoantigen in T1D and the only b-cell-spe-
cific autoantigen, as well as a major target of the auto-
immune attack mediated by T lymphocytes [1]. Moreover,
there is also a genetic association between polymorphisms of
the insulin gene and the risk to develop T1D [2]. However, in
addition to insulin, other autoantigens such as the glutamic
acid decarboxylase 65 (GAD65), islet-antigen 2 (IA2) and zinc
transporter 8 (ZnT8) have been described in T1D. They are
known to induce autoantibodies and T cell responses.
Autoantibodies against insulin or GAD isoforms are the most
common in the early phases of T1D and, occasionally, mul-
tiple auto-antibodies arise during advanced stages of the
pathology [3]. Although insulin is a primary autoantigen in
T1D, other autoantigens are involved in the progression of
the disease after epitope spreading [4].
Furthermore, in order to arrest the autoimmune reaction
against b-cells, immunological tolerance to T1D autoantigens
must be restored. A process known to promote tolerance is
efferocytosis, or phagocytosis of apoptotic cells. These dying
cells exhibit surface phosphatidylserine (PS) to be distin-
guished from living cells and to allow for their recognition by
phagocytes [5,6]. Following these principles, an antigen-spe-
cific cell immunotherapy using apoptotic b-cells was demon-
strated efficacious in re-establishing specific immunological
tolerance, which was mediated by dendritic cells (DCs) ren-
dered tolerogenic after efferocytosis [7]. Because autologous
apoptotic b-cells for T1D treatment cannot be easily
obtained, artificial cells (PS-liposomes) were generated to
mimic tolerogenic apoptotic cell function [8]. A previous
work demonstrated the therapeutic potential of PS-liposomes
encapsulating insulin peptides – as a main autoantigen in
T1D – to prevent T1D in an experimental model of the dis-
ease, the Non-Obese Diabetic (NOD) mouse [8]. The NOD
mouse, developed in 1980 [9] is considered the ‘gold-stand-
ard’ model for the study of T1D [10]. These mice develop
T1D spontaneously around 12weeks of age, after the
immune-mediated destruction of insulin-producing b cells,
commonly called insulitis. NOD mice have been extensively
utilised to study the ethiopathogenesis of the disease and to
test new immunotherapies. This model mouse closely
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resembles human disease, albeit the obvious differences with
human populations.
In order to better mimic the apoptotic b-cell, and to try to
increase the efficacy of the nanotherapy, the present study
aimed at encapsulating other peptides from several T1D
autoantigens in PS-liposomes and to test its therapeutic
effect in arresting autoimmunity. In addition, and in order to
confirm the safety of the nanotherapy, the effects of a severe
administration strategy were assessed in NOD mice.
Material and methods
Mice
Wild-type non-obese diabetic (NOD) mice were purchased
from Charles River (Calco, Lecco, Italy) and kept under spe-
cific pathogen-free conditions at the Animal House facility of
the Germans Trias i Pujol Research Institute. Mice were in a
temperature- and humidity-controlled room with 12 h light/
12h dark cycle, provided with standard chow diet (Teklad
Global 14% Protein Rodent Diet, Envigo, Sant Feliu de
Codines, Spain) and water ad libitum. To detect spontaneous
development of T1D, NOD mice were monitored daily for
urine glucose using Glucocard strips (Menarini, Barcelona,
Spain), starting at 10weeks of age and until 25weeks of age.
Mice with glycosuria were confirmed diabetic when the
blood glucose level was >300mg/dL. Mice were anesthetised
with isofluorane inhalation to obtain serum and euthanized
by cervical dislocation to harvest the pancreas at 25weeks of
age or at T1D onset. The study was approved by the
Committee on the Ethics of Animal Experimentation of the
Germans Trias i Pujol Research Institute and carried out in
strict accordance with the recommendations in the Guide for
the Care and Use of Laboratory Animals of the Generalitat de
Catalunya, Catalan Government.
Peptides and liposomes
Peptides were selected because they are target epitopes in
T1D [4]. Peptides from Insulin, C-peptide, GAD65 and IA2
(Table 1) were chosen (GL Biochem, Shanghai, China).
Peptides were >95% pure and Trifluoroacetic acid was
removed. Liposomes were composed of 1,2-dioleoyl-sn-glyc-
ero3-phospho-L-serine (sodium salt) (DOPS, Lipoid,
Steinhausen, Switzerland) and 1,2-didodecanoyl-sn-glycero-3-
phosphocholine (DLPC, Lipoid), and cholesterol (CH, Sigma
Aldrich, MO, USA). Liposomes were prepared using the thin-
film hydration method from a lipid mixture, to mimic
apoptotic bodies as described, under sterile conditions and at
a final concentration of 30mM [11]. Encapsulation efficiencies
(EE) were calculated according to the equation EE (%) ¼ [(pep-
tide, total–peptide, out)/peptide, total] 100, where peptide,
total is the initial peptide concentration and peptide, out is
the concentration of non-encapsulated peptide. To measure
the peptide, out, liposome suspensions were centrifuged at
110.000G at 10 C for 30min. The concentration of non-
encapsulated peptide was assessed in the supernatants by
PIERCE BCA protein assay kit (Thermo Fisher Scientific Inc., IL,
USA). For toxicity experiments, empty PS-liposomes were gen-
erated. The distribution of the particle size and the stability –
given as f potential – were measured by dynamic light scatter-
ing using Malvern Zetasizer (Malvern Instruments, Malvern,
UK) in undiluted samples. The morphology of liposomes was
examined by cryogenic transmission electron microscopy with
a JEOL-JEM 1400 device (Jeol Ltd., Tokyo, Japan).
T1D prevention and assessment of islet leukocytic
infiltration
Normoglycemic 8-week-old NOD mice were treated with a
single dose of liposomes. Briefly, 3.5mg of the different pep-
tide-filled PS-liposomes in 200 lL saline solution were
injected i.p. Thus, PSAB-lipo group received 200 lL of a mix
of PSA and PSB liposomes, PSGAD65-lipo group received
200 lL of a mix of PSG1 and PSG2 liposomes, PSIA2-lipo
group received 200lL of PSI1 and PSI2 liposomes and
PSCpep-lipo group received 200 lL of PSC liposomes. A
group containing 200 lL of a mix of all the different peptide-
loaded PS-liposomes (Cock-lipo) was included, in which each
liposome fraction was present in an equal amount. A group
containing the mix of all the different peptides (200lL) was
also included (Cock-Pep), the amount of peptide given being
in accordance to encapsulation efficiency inside the lipo-
somes. Sham group received saline solution. Each group con-
tained 5–9 animals. Mice were monitored daily for glycosuria
(Glucocard strips, Menarini, Barcelona, Spain) until 25weeks
of age or detection of T1D. To determine the destructive islet
leukocytic infiltration, insulitis score was assessed at 25weeks
in all non-diabetic mice. Pancreases were snap frozen in an
isopentane/cold acetone bath. Non-overlapping cryosections
(5lm) were stained with haematoxylin and eosin (H/E). A
blind analysis was performed by two independent observers,
analysing a minimum of 40 islets per animal. Insulitis was
scored as previously described: 0, no insulitis; 1, peri-insular;
2, mild insulitis (<25% of the infiltrated islet); 3, 25–75% of
the islet infiltrated; 4, >75% islet infiltration [12].
Table 1. Sequences of peptides encapsulated in PS-liposomes.
Peptide Sequence (N0–C0) Length Aminoacids
C-peptide57–87 EVEDPQVAQLELGGGPGAGDLQTLALEVAQQ 31
GAD65216–236 EYVTLKKMREIIGWPGGSGD 20
GAD65290–309 AALGIGTDSVILIKCDERGK 20
IA2816–846 GVKQCDRYWPDEGSSLYHVYEVNLVSEHIWC 31
IA2870–898 FHFLSWPAEGTPASTRPLLDFRRKVNKCY 29
Insulin90–110 (A chain) GIVDQCCTSICSLYQLENYCN 21
Insulin25–54 (B chain) FVKQHLCGSHLVEALYLVCGERGFFYTPMS 30
Subindex refers to the position of the query sequence to the protein.
GAD65: glutamic acid decarboxylase 65 ; IA2: islet-antigen 2.
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Evaluation of the toxicity of PS-liposomes
In order to determine the safety of PS-liposomes, a severe
administration strategy was tested in NOD mice. Six normo-
glycemic mice (8–12-week-old, 3 males and 3 females) were
daily injected i.p. with 200 mL of 3.5mg 30mM-lipid PS-lipo-
somes during 14 consecutive days. Simultaneously, PBS
administration was used as control (sham) in 6 mice (3 males
and 3 females). Mice health and welfare was monitored
(Supplementary Table S1) during 21 days in terms of weight,
glucosuria, physical appearance (fur, presence of secretions
or bruises) and behaviour (barbering, physical activity,
aggressiveness, stereotyped activities and pain). Mice were
euthanised at the end of the follow-up or if the total score
reached a maximum value of 3. Serum from 4 mice of each
group was analysed for biochemical parameters, such as total
cholesterol (Total CH), high-density lipoprotein (HDL) CH, tri-
glycerides, creatinine, urea and alanine transferase (ALT).
Statistical analysis
The statistical analysis was performed using the Prism 7.0
software (GraphPad software Inc., CA, USA). Mantel-Cox Log-
Rank was used to T1D incidence analysis. Mann–Whitney test
was used for comparisons of nonparametric and unpaired
data. A p-value  .05 was considered significant.
Results
PS-liposomes encapsulating insulin, but not C-peptide,
GAD65 or IA2 peptides decrease T1D incidence
Liposomes were characterised in terms of diameter, polydis-
persity index (PdI), surface charge (f-potential) and efficiency
of peptide encapsulation (Table 2). All liposomes had a final
lipid concentration of 30mM. NOD mice were treated with a
single dose of liposomes before T1D onset (8weeks old)
(Table 3). At the end of the follow-up period, T1D incidence
tended to be lower in both PSAB-lipo and Cock-Pep groups
(33.3% and 42.8%, respectively) when compared with the
sham group (66.6%) (Figure 1). Hence, and as expected, a
50%-fold reduction in T1D incidence was achieved in the
PSAB-lipo group. The groups treated with liposomes encap-
sulating IA2, GAD65 or C-peptide did not show any reduction
in the incidence of the disease (80%, 65% and 83.3% respect-
ively) when compared with sham-treated animals (Figure 1).
Moreover, the group treated with the mix of the peptide-
filled liposomes did not show a decrease in the incidence
either (80%) (Figure 1). In order to confirm that mice at the
end of follow-up did not develop T1D, urine glucose concen-
tration (glycosuria) and serum C-peptide concentration –as
indicators of b-cell function– were assessed. All mice showed
negative glycosuria and detectable C-peptide concentration
(range 900–3000 pg/mL). No statistical differences were found
between groups (data not shown).
PS-liposomes encapsulating insulin peptides reduce the
severity of the autoimmune islet destruction
Given the reduced incidence of T1D in both PSAB-lipo and
Pep-Cock treated mice, islet leukocytic infiltration was deter-
mined at the end of the follow-up period showing a bio-
logical reduction of insulitis, although non-significant, in both
treated groups (PSAB-lipo: 1.45 ± 0.57 and Cock-Pep:
1.32 ± 0.34) when compared to sham mice (1.85 ± 0.60)
(Figure 2(A)). Furthermore, the analysis of the percentages of
islets classified in each infiltration category revealed that in
both treated groups more than 64% of the islets remained
insulitis-free (type 0) or with benign insulitis (type 1); in the
control group, 48% of the islets were scored with destructive
insulitis (type 2, 3 and 4) (Figure 2(B,C)).
Table 2. Features of the liposomes used in the study.
Liposome Encapsulated peptide Diameter (nm) Polydispersity index f-potential (mV) Encapsulation efficiency (%)
PSI1 IA2816–846 459 0.236 30.8 98.69
PSI2 IA2870–898 436 0.275 31.4 72.61
PSG1 GAD65216–236 618 1.000 36.7 39.20
PSG2 GAD65290–309 440 0.285 32 31.00
PSC C peptide57–87 437 0.126 34 16.80
PSA Insulin90–110 (A chain) 712 0.364 46.6 32.29
PSB Insulin25–54 (B chain) 628 0.325 44.9 89.63
PS Empty 645 0.638 –35.9 –
Subindex of peptides refers to the position of the query sequence to the protein.
PS: Phosphatidylserine-rich liposomes; GAD65: glutamic acid decarboxylase 65 ; IA2: islet-antigen 2.
Table 3. Amount of peptide encapsulated in a dose (200 mL) of PS-liposomes
(3.5mg lipid).
Treatment Peptide Peptide per dose (mg)
PSG GAD65216–236 39,2
GAD65290–309 31
PSI IA2816–846 98,69
IA2870–898 72,61
PSC C-peptide57–87 16,8
PSAB Insulin (A-chain)90–110 32,29
Insulin (B chain)25–54 89,63
Cock-Pep GAD65216–236 14,28
GAD65290–309 14,28
IA2816–846 14,28
IA2870–898 14,28
C-peptide57–87 14,28
Insulin90–110 14,28
Insulin25–54 14,28
Cock-lipo GAD65216–236 5,59
GAD65290–309 4,42
IA2816–846 14,09
IA2870–898 10,37
C-peptide57–87 2,40
Insulin90–110 4,61
Insulin25–54 13,26
Cock-Pep: mixture of all non-encapsulated peptides; Cock-lipo: mixture of all
PS-liposomes encapsulating different peptides.
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PS-liposomes treatment demonstrated optimal safety
and tolerability in NOD mice
The observational study, taking into account the criteria used
in welfare monitoring of mice used for toxicity and tolerabil-
ity assays (Supplementary Table S1), demonstrated the safety
of daily PS-liposomes administration in NOD mice. Only mild
complications were observed both in daily PS-liposomes-
treated and sham group (Table 4) and no animal had to be
euthanised due to severe complications of the treatment. All
mice were negative for glucosuria during the 14 days of treat-
ment and 7 days after withdrawal. The analysis of the serum
showed no significant differences between PS-liposomes and
Figure 1. T1D incidence in NOD mice treated with PS-liposomes filled with different autoantigenic peptides. Cumulative incidence (percentage) of T1D in NOD
mice treated with IA2 liposomes (PSIA2-lipo, blue, n¼ 5), GAD65 liposomes (PSGAD65-lipo, red, n¼ 6), C-peptide liposomes (PSCpep-lipo, yellow, n¼ 6), insulin lip-
osomes (PSAB-lipo, grey, n¼ 6), a mixture of all liposomes (Cock-lipo, green, n¼ 5) and a mixture of all non-encapsulated peptides (Cock-Pep, black, n¼ 7). A sham
group was also included (violet, n¼ 9). The arrow indicates the time-point of the single-dose administration (at 8 weeks). No significant differences in T1D incidence
were found between groups (Mantel-Cox Log-Rank). PSIA2-lipo: IA2 liposomes; PSGAD65-lipo: GAD65 liposomes; Cock-lipo: a mixture of all liposomes; PSCpep-lipo:
C-peptide liposomes; Cock-Pep: a mixture of all non-encapsulated peptides; PSAB-lipo: insulin liposomes.
Figure 2. Islet leukocytic infiltrate (insulitis) following administration of nanotherapy. (A) Insulitis score from non-diabetic mice at the end of the follow-up period
at 25weeks, including the PSAB-lipo (n¼ 3), Cock-Pep (n¼ 3) and sham (n¼ 3) groups. Results are mean ± Standard Deviation (SD). No statistical differences were
found between groups (Mann-Whitney test). (B) Percentage of islets in each of the infiltration categories: White ¼ 0, no insulitis; Dotted ¼ 1, peri-insular; Striped ¼
2, mild insulitis (<25% of the infiltrated islet); Squared ¼ 3, 25–75% of the islet infiltrated; Black ¼ 4, >75% islet infiltration. (C) Representative images of insulitis
in islets from H/E-pancreatic cryostat sections (5mm) from the three different groups. Scale bar represents 100 mm. PSAB-lipo: insulin PS-liposomes; Cock-Pep: mix-
ture of all non-encapsulated peptides.
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sham groups at the end of the study (Figure 3). Total CH,
HDL CH, triglycerides and ALT concentrations remained
unaltered and within reference values for NOD mice [13].
Urea concentration in both the groups was found above ref-
erence values. Creatinine concentration was similar in both
groups, but reference values were not available.
Discussion
This study shows that the administration of PS-liposomes
encapsulating insulin peptides is the best strategy to reduce
the incidence of T1D, spontaneously developed in NOD mice,
when compared to other encapsulated autoantigen peptides
(GAD65, IA2 and C-peptide). Liposomes are vesicles com-
posed of lipid bilayers that can be used as a vehicle for drug
delivery. Considering that the physicochemical features of
the liposomes are homogeneous, and that empty liposomes
have no effect on T1D and other autoimmune diseases [8,14],
the differences here reported can be due to the biological
features of the encapsulated autoantigens. The role of the
different autoantigens in the stages of autoimmunity in T1D
is also relevant. On the one hand, insulin is the most
expressed specific autoantigen in the target b-cells on which
the autoimmune reaction is focussed and, on the other hand,
single positivity for autoantibodies against insulin but not for
the rest of autoantigens is associated with the greatest risk
to develop T1D [15]. Moreover, it has been described that
insulin is an early autoantigen in T1D whereas the other
autoantigens seem to be the consequence of epitope spread-
ing, after the activation of autoimmunity [15]. IA2 expression
is not exclusive of pancreatic b-cells in humans nor rodents,
being found expressed also in many neuroendocrine cells
[16–18]. This lack of specificity would explain the unsuccess-
ful therapeutic use by its single encapsulation in PS-lipo-
somes. GAD65 expression is also present in other tissues due
to its role in the biosynthesis of gamma-aminobutyric acid
(GABA) like GABAergic cells [19]. Furthermore, it has been
recently reported that GAD65 has no capacity to prevent T1D
in wild type NOD mice [20]. Finally, the role of C-peptide as
autoantigen in T1D remained controversial despite recent
work hints at its action as an autoantigen [21–23]. This work
validates the use of PS-liposomes encapsulating insulin pepti-
des to prevent the development of autoimmune T1D and
tends to reduce the insulitis in the experimental NOD
model [8].
A different encapsulation efficiency has been observed for
the different peptides and this fact must be taken into
Table 4. NOD mice daily treated with PS-liposomes (14 days) with
disturbances.
Parameter
Mice with disturbances
Sham PS-liposomes
Loss of 10% of body weight 1/6 (16%) 2/6 (33%)
Piloerection 0/6 (0%) 1/6 (16%)
Mild bruises on the abdomen 1/6 (16%) 0/6 (0%)
Mild bruises on the tail 1/6 (16%) 0/6 (0%)
Mild aggressive behaviour 0/6 (0%) 1/6 (16%)
Data presented as number of mice with disturbances in each group and per-
centage (%).
Figure 3. Effect of daily administration of PS-liposomes on blood biochemical parameters of NOD mice at the end of the study (Day 21). In vivo toxicity assay by
measuring the levels of (A) Total CH, mg/dL, (B) HDL CH, mg/dL), (C) triglycerides (mg/dL), (D) ALT, U/L, (E) urea, mg/dL and (F) creatinine, mg/dL in serum of PBS-
treated mice (n¼ 4, squares) and PS-liposomes-treated mice (n¼ 4, circles), at the end of the study (Day 21). Continuous lines represent the mean of each group.
The grey area depicts normal ranges of parameters and the median (discontinuous line) of the different analytes for NOD mice. Significant differences were not
found between groups (Mann-Whitney test). CH: cholesterol; ALT: Alanine transferase.
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account to both understand the results in this study and to
design future nanotherapies. The lowest percentage of
encapsulation corresponds to liposomes encapsulating C-
peptide and, as mentioned above, the role of this molecule
as autoantigen remains unclear. Both facts may be the reason
of the lack of effect in T1D prevention. Moreover, the mixture
of liposomes (Cock-lipo) contains a 7-fold reduction of the
total insulin peptide amount carried in the PSAB-lipo, result-
ing in a loss of therapeutic action.
Apart from the nanotherapy described here, a mixture of
the selected autoantigens (Cock-Pep) was found to reduce
the incidence of the disease when compared with the sham
group but with a minor effect than the observed with PS-lip-
osomes encapsulating insulin. The synergistic effect of PS in
the liposomes and the encapsulated peptide has been
described in previous work showing a tolerogenic effect
mediated by DCs [8]. Many therapies have been tested both
for prevention and treatment of T1D in the NOD mice based
on peptides [24]. The here reported effect of combined pep-
tides fits well with previous data showing a preventive effect
of T1D after peptide administration of insulin, GAD65 and
IA2 in NOD mice and in other autoimmune models [25,26].
This works shows that the choice of autoantigen and
derived peptides is key in the design of vesicles for T1D
immunotherapies. Despite that, questions still remain about
the therapeutic contribution of each peptide and about the
molecular mechanisms involved in their immune-recognition.
Of note, the timing of administration of nanotherapies to
arrest spontaneous autoimmunity in T1D plays an essential
role in the success of the immunotherapy. Moreover, the
best peptide option for encapsulation in nanovesicles will
probably depend not only on the checkpoint of intervention
but also on the immunophenotype (specific autoantibodies
and autoreactive T cells) of each patient.
A vital issue for the successful implementation of the PS-
liposomes immunotherapy in the clinics is its potential
toxicity and tolerability. The daily injections of PS-liposomes
during two weeks, revealed a well-tolerated and safe profile
in NOD mice. The minor complications found among both
groups are probably due to the stress of the injections the
mice received daily. Also, the loss of 10% of body weight
reported in mice in both the groups suggests that these
mice were on the road to developing diabetes. The analysis
of the serum confirmed the safety of the treatment.
We are fully aware that they are preliminary results and
that a low number of mice have been analysed. Further stud-
ies are required to validate the tendencies observed in a
larger group of mice and over a longer period of time, and
to determine the effect of the therapy in several tissues by
histological analyses. However, the effect of only one dose of
PS-liposomes encapsulating autoantigens is clear and
resulted in T1D prevention without side-effects, providing a
simple and innovative system to recover self-tolerance.
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